Immunovant (NASDAQ:IMVT) Shares Gap Down – What’s Next?

Immunovant, Inc. ( NASDAQ:IMVT – Get Free Report )’s stock price gapped down prior to trading on Friday . The stock had previously closed at $25.

19, but opened at $24.52. Immunovant shares last traded at $25.



20, with a volume of 32,596 shares trading hands. Wall Street Analyst Weigh In A number of equities analysts have recently weighed in on IMVT shares. Wolfe Research downgraded Immunovant from an “outperform” rating to a “peer perform” rating in a research note on Friday.

Raymond James reissued an “outperform” rating and issued a $36.00 price objective on shares of Immunovant in a research report on Thursday, October 10th. Oppenheimer raised their target price on Immunovant from $47.

00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, October 9th. Wells Fargo & Company cut their price target on shares of Immunovant from $47.

00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Finally, HC Wainwright restated a “buy” rating and set a $51.

00 price objective on shares of Immunovant in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.

com, the company presently has an average rating of “Moderate Buy” and an average target price of $47.22. Get Our Latest Stock Analysis on Immunovant Immunovant Stock Performance Immunovant ( NASDAQ:IMVT – Get Free Report ) last announced its quarterly earnings results on Thursday, November 7th.

The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.

15). During the same quarter in the prior year, the firm posted ($0.45) earnings per share.

As a group, equities research analysts predict that Immunovant, Inc. will post -2.73 EPS for the current year.

Insider Transactions at Immunovant In other news, CFO Eva Renee Barnett sold 5,162 shares of the company’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $29.56, for a total value of $152,588.

72. Following the transaction, the chief financial officer now owns 338,614 shares of the company’s stock, valued at approximately $10,009,429.84.

This represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website .

Also, insider William L. Macias sold 3,188 shares of Immunovant stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $28.

79, for a total value of $91,782.52. Following the sale, the insider now directly owns 365,144 shares of the company’s stock, valued at $10,512,495.

76. This represents a 0.87 % decrease in their position.

The disclosure for this sale can be found here . Over the last ninety days, insiders have sold 77,659 shares of company stock valued at $2,096,890. 5.

90% of the stock is currently owned by corporate insiders. Institutional Inflows and Outflows Institutional investors have recently modified their holdings of the stock. KBC Group NV grew its stake in Immunovant by 46.

2% in the 3rd quarter. KBC Group NV now owns 1,936 shares of the company’s stock worth $55,000 after buying an additional 612 shares in the last quarter. Quest Partners LLC lifted its holdings in shares of Immunovant by 216.

7% during the 2nd quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock worth $69,000 after acquiring an additional 1,786 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Immunovant during the 2nd quarter worth $77,000.

Assetmark Inc. grew its position in Immunovant by 73.8% in the third quarter.

Assetmark Inc. now owns 2,891 shares of the company’s stock worth $82,000 after acquiring an additional 1,228 shares in the last quarter. Finally, Mirae Asset Global Investments Co.

Ltd. increased its stake in Immunovant by 21.4% in the third quarter.

Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock valued at $148,000 after acquiring an additional 934 shares during the last quarter.

47.08% of the stock is currently owned by institutional investors. About Immunovant ( Get Free Report ) Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. Read More Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter .

.